| Felipe Santos, MD | |
|
243 Charles St, Boston, MA 02114-3096 | |
| (617) 573-3936 | |
| Not Available |
| Full Name | Felipe Santos |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 22 Years |
| Location | 243 Charles St, Boston, Massachusetts |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1841309580 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Y00000X | Otolaryngology | 246671 (Massachusetts) | Primary |
| 207YX0901X | Otolaryngology - Otology & Neurotology | A107293 (California) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Massachusetts Eye And Ear Infirmary - | Boston, MA | Hospital |
| Massachusetts General Hospital | Boston, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Massachusetts Eye And Ear Associates, Inc | 4486540275 | 337 |
News Archive
Employers are effectively controlling drug benefit costs and utilization, according to research findings in the Pharmacy Benefit Management Institute's (PBMI) 2009-2010 Prescription Drug Benefit Cost and Plan Design Report. PBMI's employer survey shows the average rate of increase in drug costs has dropped to 4.4%, the lowest rate of increase since PBMI began conducting the study in 1995.
A diagnostic test for tuberculosis (TB) can accurately and quickly detect both TB and drug-resistant strains, according to a new study. The authors of a new systematic review assessing the diagnostic accuracy of the Xpert® MTB/RIF test published in The Cochrane Library say their study can provide timely advice for clinicians and policymakers in countries where TB is a major public health problem.
A study in military veterans finds that explosive blast-related concussions frequently result in hormone changes leading to problems such as sleep disturbances, fatigue, depression and poor quality of life. The research, to be presented Saturday at the Endocrine Society's 98th annual meeting in Boston, evaluated hormone levels in 41 male veterans who had been deployed to Iraq or Afghanistan.
Vicus Therapeutics, LLC, today announced the initiation of a Phase 2 trial evaluating VT-122, a novel investigational combination of etodolac and propranolol, and Nexavar® (sorafenib) tablets, as a potential new treatment option for patients with advanced liver cancer (hepatocellular carcinoma), systemic inflammation and cachexia.
› Verified 4 days ago
| Entity Name | Massachusetts Eye And Ear Associates, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1932574332 PECOS PAC ID: 4486540275 Enrollment ID: O20040227000123 |
News Archive
Employers are effectively controlling drug benefit costs and utilization, according to research findings in the Pharmacy Benefit Management Institute's (PBMI) 2009-2010 Prescription Drug Benefit Cost and Plan Design Report. PBMI's employer survey shows the average rate of increase in drug costs has dropped to 4.4%, the lowest rate of increase since PBMI began conducting the study in 1995.
A diagnostic test for tuberculosis (TB) can accurately and quickly detect both TB and drug-resistant strains, according to a new study. The authors of a new systematic review assessing the diagnostic accuracy of the Xpert® MTB/RIF test published in The Cochrane Library say their study can provide timely advice for clinicians and policymakers in countries where TB is a major public health problem.
A study in military veterans finds that explosive blast-related concussions frequently result in hormone changes leading to problems such as sleep disturbances, fatigue, depression and poor quality of life. The research, to be presented Saturday at the Endocrine Society's 98th annual meeting in Boston, evaluated hormone levels in 41 male veterans who had been deployed to Iraq or Afghanistan.
Vicus Therapeutics, LLC, today announced the initiation of a Phase 2 trial evaluating VT-122, a novel investigational combination of etodolac and propranolol, and Nexavar® (sorafenib) tablets, as a potential new treatment option for patients with advanced liver cancer (hepatocellular carcinoma), systemic inflammation and cachexia.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Felipe Santos, MD 243 Charles St, Boston, MA 02114-3096 Ph: (617) 573-3936 | Felipe Santos, MD 243 Charles St, Boston, MA 02114-3096 Ph: (617) 573-3936 |
News Archive
Employers are effectively controlling drug benefit costs and utilization, according to research findings in the Pharmacy Benefit Management Institute's (PBMI) 2009-2010 Prescription Drug Benefit Cost and Plan Design Report. PBMI's employer survey shows the average rate of increase in drug costs has dropped to 4.4%, the lowest rate of increase since PBMI began conducting the study in 1995.
A diagnostic test for tuberculosis (TB) can accurately and quickly detect both TB and drug-resistant strains, according to a new study. The authors of a new systematic review assessing the diagnostic accuracy of the Xpert® MTB/RIF test published in The Cochrane Library say their study can provide timely advice for clinicians and policymakers in countries where TB is a major public health problem.
A study in military veterans finds that explosive blast-related concussions frequently result in hormone changes leading to problems such as sleep disturbances, fatigue, depression and poor quality of life. The research, to be presented Saturday at the Endocrine Society's 98th annual meeting in Boston, evaluated hormone levels in 41 male veterans who had been deployed to Iraq or Afghanistan.
Vicus Therapeutics, LLC, today announced the initiation of a Phase 2 trial evaluating VT-122, a novel investigational combination of etodolac and propranolol, and Nexavar® (sorafenib) tablets, as a potential new treatment option for patients with advanced liver cancer (hepatocellular carcinoma), systemic inflammation and cachexia.
› Verified 4 days ago
Dr. Steven D. Rauch, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 243 Charles St, Boston, MA 02114 Phone: 617-523-7900 | |
Elliott D. Kozin, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 243 Charles St, Boston, MA 02114 Phone: 617-573-6545 | |
Katherine Nicole Vandenberg, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 830 Harrison Ave Ste 1400, Boston, MA 02118 Phone: 617-638-8124 | |
Yoon Sun Chun, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 75 Francis St, Brigham And Women's Hospital Dept Of Plastic Surgery, Boston, MA 02115 Phone: 617-732-8181 Fax: 617-983-4534 | |
Jaimie Derosa, M.D. Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 91 Newbury St, Suite 300, Boston, MA 02116 Phone: 617-262-8000 Fax: 617-262-8002 | |
Dr. Usama M Aboelkheir, MD Otolaryngology Medicare: Medicare Enrolled Practice Location: 736 Cambridge St, Smc8, Boston, MA 02135 Phone: 617-789-5004 Fax: 617-779-6481 | |
Phillip C Song, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 243 Charles St, Boston, MA 02114 Phone: 617-573-3557 |